TUESDAY 21st SEPTEMBER

12.45-13.10 VIRTUAL EXHIBITION

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.10-13.15</td>
<td>Introduction and Welcome by Dr Varuna Aluvihare (Chair BLTG)</td>
</tr>
<tr>
<td>13.17-13.32</td>
<td>A collaborative approach to benefit patients</td>
</tr>
<tr>
<td></td>
<td>“Collaboration during the pandemic had a positive outcome.”</td>
</tr>
<tr>
<td></td>
<td>Prof Doug Thorburn (Hepatologist, Royal Free) &amp; Ms Rhiannon Taylor (Senior Statistician, NHSBT)</td>
</tr>
<tr>
<td>13.34-13.54</td>
<td>Overcoming barriers to referral</td>
</tr>
<tr>
<td></td>
<td>“The factor that most influenced a unit’s ability to assess for transplantation was a lack of referrals from the catchment area.”</td>
</tr>
<tr>
<td></td>
<td>Dr Richard Aspinall (Hepatologist, Portsmouth) &amp; Dr Varuna Aluvihare (Hepatologist, Kings)</td>
</tr>
<tr>
<td>13.54-14.00</td>
<td>BREAK</td>
</tr>
<tr>
<td>14.00-14.20</td>
<td>Standardising the transplant assessment process – to list or not to list?</td>
</tr>
<tr>
<td></td>
<td>“Prioritising when considering the risk benefit ratio of transplantation differed between units; and the potential movement of patients between transplant units highlighted our need to standardise.”</td>
</tr>
<tr>
<td></td>
<td>Panel discussion – Metabolic syndrome/frailty</td>
</tr>
<tr>
<td></td>
<td>Case presented by: TBC</td>
</tr>
<tr>
<td></td>
<td>Panel: Dr Matt Armstrong (Hepatologist, Birmingham); Dr Rebecca Jones (Hepatologist, Leeds); Dr John Klinck (Anaesthetist, Cambridge); Dr John Isaac (Anaesthetist, Birmingham)</td>
</tr>
<tr>
<td>14.22-14.42</td>
<td>Panel discussion – Alcohol</td>
</tr>
<tr>
<td></td>
<td>Case presented by: TBC</td>
</tr>
<tr>
<td></td>
<td>Panel: Dr Steve Masson (Hepatologist, Newcastle); Dr Andrew Bathgate (Hepatologist, Edinburgh); Dr Mike Allison (Hepatologist, Cambridge); Mr Kerry Webb (Nurse Consultant, Birmingham)</td>
</tr>
<tr>
<td>14.44-15.14</td>
<td>Best transplant abstracts x 2</td>
</tr>
<tr>
<td>15.14-15.40</td>
<td>BREAK &amp; VIRTUAL EXHIBITION</td>
</tr>
<tr>
<td>15.40-16.00</td>
<td>Ensuring the resources are in place</td>
</tr>
<tr>
<td></td>
<td>“Transplant staff were not seen as a priority - with widespread redeployment.”</td>
</tr>
<tr>
<td></td>
<td>Panel discussion – Work force planning</td>
</tr>
<tr>
<td></td>
<td>Panel: Dr Andrew Holt (Hepatologist, Birmingham); Prof Brian Davidson (Surgeon, Royal Free); Mr Derek Manas (Surgeon, Newcastle); Mr Shahid Farid (Surgeon, Leeds); Dr Agimol Pradeep (Liver transplant co-ordinator, Kings); TBC (Hepatologist);</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>16.02-16.22</td>
<td>TBC (Commissioning)</td>
</tr>
<tr>
<td></td>
<td><em>National service evaluation: Current challenges in liver ITU</em></td>
</tr>
<tr>
<td></td>
<td>Dr Brian Hogan <em>(Hepatologist and Intensivist, Kings)</em></td>
</tr>
<tr>
<td>16:22-16:25</td>
<td>BREAK</td>
</tr>
<tr>
<td>16.25-16.55</td>
<td>Williams Calne Lecture: Expanding the donor pool for liver transplantation</td>
</tr>
<tr>
<td></td>
<td>Prof Robert J Porte <em>(University Medical Center Groningen, The Netherlands)</em></td>
</tr>
<tr>
<td>16.55-17.00</td>
<td>Final comments and close by Dr Varuna Aluvihare</td>
</tr>
</tbody>
</table>
WEDNESDAY 22ND SEPTEMBER

10.30-11.15 – Industry symposium – Shionogi
11.30-12.15 – Industry symposium – Grifols UK Ltd
11.30-12.15 – Industry symposium – Gilead

12.15-12.50  VIRTUAL EXHIBITION

12.50-12.58  Welcome by BASL President

Technology in Translation symposium
13.00-13.20  Digital technology for community management of fatty liver
Prof Suzanne Norris
13.20-13.40  Faecal microbiota transplantation for chronic liver disease
Prof Debbie Shawcross
13.40-13.55  Raman spectroscopy for liver biology and pathology
Colin Campbell
13.55-14.15  Panel Discussion

14.15-14.20  BREAK

14.20-14.50  Dame Sheila Sherlock Research Award
TBA
Dr Upkar Gill

14.50-15.25  BREAK & VIRTUAL EXHIBITION

Free Papers
15.25-15.35  O03 (38) - A novel nurse-led early post-discharge clinic is associated
with fewer readmissions and lower mortality following an index
hospitalisation with decompensated cirrhosis
Dr Benjamin Giles

15.35-15.45  O04 (42) - Serum nuclear magnetic resonance metabolomic signature
can discriminate immunoglobulin G4-related sclerosing cholangitis
and primary sclerosing cholangitis
Dr Emmanuel Selvaraj

15.45-15.55  O06 (66) - Aminobisphosphonates enhance liver-resident gamma
delta T cells for efficient targeting of hepatocellular carcinoma
Dr Nekisa Zakeri

15.55-16.05  O08 (84) - Dietary factors underlying non-alcoholic fatty liver disease
(NAFLD) and its severity: a large, population-based, case-control
study.
Amina Al-Awadi

This meeting is supported by way of purchase of sponsorship or exhibition space by the companies listed in the exhibition area and is limited to meeting the cost of the scientific meeting with no input to the programme.
16.05-16.15  BREAK

16.15-16.45  Ralph Wright Lecture
Curing Chronic Hepatitis B
Prof Geoff Dusheiko

16.45-16.50  Day Closing remarks and close
THURSDAY 23RD SEPTEMBER

10.30-11.15 – Industry symposium – Intercept
11.30-12.15 – Industry symposium – Norgine

12.15-12.50 **VIRTUAL EXHIBITION**

**Rapid Updates – Part 1**
13.00-13.10 ALF
13.10-13.20 Alcohol-related Liver
13.20-13.30 CCA-UK
13.30-13.40 End of Life
13.40-13.50 HBV
13.50-14.00 HCC-UK

14.00-14.05 **BREAK**

**Rapid Updates – Part 2**
14.05-14.15 Autoimmune Liver
14.15-14.25 NAFLD
14.25-14.35 Portal Hypertension
14.35-14.45 Acute on Chronic Liver Failure
14.45-14.55 Pathology
14.55-15.05 Paediatrics

15.05-15.35 **BREAK & VIRTUAL EXHIBITION**

15.35-16.05 **Andy Burroughs Young Investigator Award**
TBC
Dr Fotios Sampaziotis

16.07-16.22 National Survey of Primary care pathways from liver disease
TBC

16.24-16.59 **Introduction to BLT Lecture**
Pamela Healy
**British Liver Trust Lecture**
Diagnostics for liver disease: Recovery and renewal
TBC

16.59-17.05 **BREAK**

17.05-17.20 UK Liver Alliance
TBC

This meeting is supported by way of purchase of sponsorship or exhibition space by the companies listed in the exhibition area and is limited to meeting the cost of the scientific meeting with no input to the programme
Free Papers

17.22-17.32  O09 (105) - A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients
Dr Jane Macnaughtan

17.32-17.42  O10 (112) - Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure; results of the first multicenter randomized trial (GRAFT study)
Dr Cornelius Engelmann

17.42-17.47  Day Closing remarks and close
FRIDAY 24TH SEPTEMBER

10.30-11.15 – Industry symposium – SIRTeX

12.15-12.45 VIRTUAL EXHIBITION

Rare Disease Symposium
12.45-13.05 Alpha1 Antitrypsin deficiency related Liver disease: Targets, treatments and outcomes
   Prof David Lomas, UCL
13.05-13.25 Wilson's disease: New Developments
   Dr Mike Schilsky, Yale
13.25-13.45 Porphyria: Interventions
   Dr Bruce Wang, UCSF
13.45-14.00 Panel Discussion

14.00-14.05 BREAK

14.05-14.50 BASL Annual Business Meeting

14.50-15.15 BREAK & VIRTUAL EXHIBITION

Free Papers
15.15-15.25 O01 (4) - Genetic analysis and phenotypic correlation in ductal plate malformation
   Dr Meha Bhuva

15.25-15.35 O02 (21) - Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ecto nucleotidase CD73 as a potential therapeutic target.
   Dr Rosemary Faulkes

15.35-15.45 O05 (57) - Opportunities to intervene after early detection of alcohol related liver disease
   Dr Tiwonge Jason Nyirenda

15.45-15.55 O07 (73) - FXR antagonists as new agents for COVID19
   Teresa Brevini

15.55-16.00 BREAK

16.00-16.30 Alex Mowat Lecture - Progressive Familial Intrahepatic Cholestasis: Discovery to Disease modifying drugs
   Dr William Balistreri, Cincinatti

16.30-16.35 Closing remarks and close

This meeting is supported by way of purchase of sponsorship or exhibition space by the companies listed in the exhibition area and is limited to meeting the cost of the scientific meeting with no input to the programme.